NEW YORK, May 31 - Aventis Pharma and chemical microarray developer Graffinity Pharmaceutical Design have signed a collaboration to identify leads for Aventis' drug targets, the two companies said Thursday. 

Financial details were not disclosed.

Graffinity, based in Heidelberg, Germany, has developed small-molecule microarrays that identify which compounds bind favorably with a protein drug target. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.